论文部分内容阅读
目的探讨采用丹参酮IIA磺酸钠注射液治疗过敏性紫癜对患者紫癜消退及肾受累的影响。方法选取2013年8月至2014年10月已确诊为过敏性紫癜的患者68例,每组34例。采用随机数字表将患者分为实验组和对照组,每组34例。对照组给予常规治疗,实验组在常规治疗的基础上加静脉滴注丹参酮IIA磺酸钠注射液。观察两组过敏性紫癜患者紫癜消退情况及肾脏受累情况。结果入院时两组各有6例为肾型紫癜,基础肾受累率相当(P>0.05);入院后新发肾脏受累实验组2例(5.88%),对照组9例(26.47%),新发肾脏受累率实验组明显低于对照组,差异有统计学意义(P<0.05)。且治疗后实验组原6例肾型紫癜患者肾脏损害减轻,逐渐转为镜下血尿;而对照组原6例肾型紫癜的肾脏损害几乎无改善。结论在常规治疗基础上加用丹参酮IIA磺酸钠注射液治疗过敏性紫癜,可降低患者的肾脏受累率,改善肾脏损害程度。
Objective To investigate the effect of tanshinone IIA sodium sulfonate injection on the treatment of Henoch-Schonlein purpura in patients with purpura and renal involvement. Methods From August 2013 to October 2014, 68 patients with allergic purpura were diagnosed, 34 cases in each group. Patients were divided into experimental group and control group using random number table, 34 cases in each group. The control group was given routine treatment. The experimental group was given intravenous infusion of tanshinone IIA sodium sulfonate on the basis of routine treatment. Observe the two groups of patients with Henoch-Schonlein purpura regression and renal involvement. Results There were 6 cases of renal purpura in each group, and the basic renal involvement rate was similar (P> 0.05). There were 2 cases (5.88%) in the newly diagnosed renal involvement group and 9 cases (26.47%) in the control group The rate of renal involvement in experimental group was significantly lower than that in control group, the difference was statistically significant (P <0.05). And after treatment, the experimental group, the original 6 cases of renal purpura reduce renal damage, and gradually turned to microscopic hematuria; while the control group, the original 6 cases of renal purpura renal almost no improvement. Conclusion The addition of tanshinone IIA sodium sulfonate injection on the basis of routine treatment of Henoch-Schonlein purpura can reduce the renal involvement rate and improve the degree of renal damage.